What is it about?
Considers the fundamental falsification assymetry in clinical trials especially as this effects claims of equivalence. Shows that the value of blinding is only fully asserted is a difference is found.
Featured Image
Why is it important?
First article (as far as I am aware) to point out a problem in claiming that an equivalance study was blind.
Read the Original
This page is a summary of: Falsificationism and clinical trials, Statistics in Medicine, November 1991, Wiley,
DOI: 10.1002/sim.4780101106.
You can read the full text:
Resources
Contributors
The following have contributed to this page
